Sanggenon ACAS# 76464-71-6 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 76464-71-6 | SDF | Download SDF |
PubChem ID | 156707 | Appearance | Powder |
Formula | C25H24O7 | M.Wt | 436.5 |
Type of Compound | Phenols | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (3R,11S)-7,11,14-trihydroxy-18,18-dimethyl-3-(3-methylbut-2-enyl)-2,10,19-trioxapentacyclo[11.8.0.03,11.04,9.015,20]henicosa-1(13),4(9),5,7,14,16,20-heptaen-12-one | ||
SMILES | CC(=CCC12C3=C(C=C(C=C3)O)OC1(C(=O)C4=C(O2)C=C5C(=C4O)C=CC(O5)(C)C)O)C | ||
Standard InChIKey | WDKDKBZGSVJWSD-JWQCQUIFSA-N | ||
Standard InChI | InChI=1S/C25H24O7/c1-13(2)7-10-24-16-6-5-14(26)11-18(16)32-25(24,29)22(28)20-19(31-24)12-17-15(21(20)27)8-9-23(3,4)30-17/h5-9,11-12,26-27,29H,10H2,1-4H3/t24-,25-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Sanggenon A Dilution Calculator
Sanggenon A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.291 mL | 11.4548 mL | 22.9095 mL | 45.819 mL | 57.2738 mL |
5 mM | 0.4582 mL | 2.291 mL | 4.5819 mL | 9.1638 mL | 11.4548 mL |
10 mM | 0.2291 mL | 1.1455 mL | 2.291 mL | 4.5819 mL | 5.7274 mL |
50 mM | 0.0458 mL | 0.2291 mL | 0.4582 mL | 0.9164 mL | 1.1455 mL |
100 mM | 0.0229 mL | 0.1145 mL | 0.2291 mL | 0.4582 mL | 0.5727 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Sanggenol G
Catalog No.:BCX0456
CAS No.:202526-52-1
- (-)-3-Hydroxy-p-menth-1-en-6-one
Catalog No.:BCX0455
CAS No.:78085-72-0
- 21,23-Dihydro-21-hydroxy-23-oxonomilinic acid methyl ester
Catalog No.:BCX0454
CAS No.:2243600-34-0
- 6'-O-Glucopyranosylpaeoniflorin
Catalog No.:BCX0453
CAS No.:1427054-21-4
- Zerumin B
Catalog No.:BCX0452
CAS No.:176050-49-0
- Isoscutellarein 8-O-glucuronide
Catalog No.:BCX0451
CAS No.:56317-09-0
- (2E,4E)-6-Hydroxy-2,6-dimethylhepta-2,4-dienal
Catalog No.:BCX0450
CAS No.:220766-63-2
- 7,4'-Dihydroxyflavone 7-O-glucoside
Catalog No.:BCX0449
CAS No.:20633-86-7
- Zerumin
Catalog No.:BCX0448
CAS No.:180680-70-0
- 14-Deoxyisocoronarin D
Catalog No.:BCX0447
CAS No.:189239-51-8
- Morofficinaloside
Catalog No.:BCX0446
CAS No.:78964-45-1
- Durianol A
Catalog No.:BCX0445
CAS No.:1941203-91-3
- Sanggenon M
Catalog No.:BCX0458
CAS No.:922080-11-0
- Breynioside A
Catalog No.:BCX0459
CAS No.:63555-02-2
- 6'-O-Glucopyranosylalbiflorin
Catalog No.:BCX0460
CAS No.:1001644-88-7
- (E)-14-Hydroxy-15-norlabda-8(17),12-dien-16-al
Catalog No.:BCX0461
CAS No.:114370-19-3
- Monardin C
Catalog No.:BCX0462
CAS No.:1262796-93-9
- 15-O-Ethylzerumin B
Catalog No.:BCX0463
CAS No.:1707019-00-8
- Alpinenone
Catalog No.:BCX0464
CAS No.:103425-23-6
- 6β-Hydroxy-7-epi-α-cyperone
Catalog No.:BCX0465
CAS No.:6851-55-4
- Zataroside A
Catalog No.:BCX0466
CAS No.:95645-53-7
- Procumboside A
Catalog No.:BCX0467
CAS No.:850894-16-5
- Moracin B
Catalog No.:BCX0468
CAS No.:67259-16-9
- Sanggenol F
Catalog No.:BCX0469
CAS No.:202526-51-0
Kuwanon T and Sanggenon a Isolated from Morus alba Exert Anti-Inflammatory Effects by Regulating NF-kappaB and HO-1/Nrf2 Signaling Pathways in BV2 and RAW264.7 Cells.[Pubmed:34946724]
Molecules. 2021 Dec 16;26(24):7642.
We previously investigated the methanolic extract of Morus alba bark and characterized 11 compounds from the extract: kuwanon G (1), kuwanon E (2), kuwanon T (3), Sanggenon A (4), sanggenon M (5), sanggenol A (6), mulberofuran B (7), mulberofuran G (8), moracin M (9), moracin O (10), and norartocarpanone (11). Herein, we investigated the anti-inflammatory effects of these compounds on microglial cells (BV2) and macrophages (RAW264.7). Among them, 3 and 4 markedly inhibited the lipopolysaccharide (LPS)-induced production of nitric oxide in these cells, suggesting the anti-inflammatory properties of these two compounds. These compounds inhibited the production of prostaglandin E2, interleukin-6, and tumor necrosis factor-alpha, and the expression of inducible nitric oxide synthase and cyclooxygenase-2 following LPS stimulation. Pretreatment with 3 and 4 inhibited the activation of the nuclear factor kappa B signaling pathway in both cell types. The compounds also induced the expression of heme oxygenase (HO)-1 through the activation of nuclear factor erythroid 2-related factor 2. Suppressing the activity of HO-1 reversed the anti-inflammatory effects caused by pretreatment with 3 and 4, suggesting that the anti-inflammatory effects were regulated by HO-1. Taken together, 3 and 4 are potential candidates for developing therapeutic and preventive agents for inflammatory diseases.